Sight Sciences, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing reveals a company at a crossroads, balancing impressive commercial acceleration in dry eye treatment against a persistent burn rate. The 12.5% revenue growth and the successful navigation of the Alcon legal battle provide a strong bullish signal, suggesting that the company's intellectual property and market access strategies are working. However, the underlying financial instability—characterized by high-interest debt and a shrinking cash pile—serves as a critical counterweight. Investors are now weighing the certainty of the Alcon royalties and the scalability of the TearCare system against the risk of pipeline stagnation due to R&D cuts. The overall impact of the filing is a transition from a pure-play R&D firm to a commercial-stage entity that must now prove it can achieve positive cash flow without further diluting shareholders or incurring additional high-cost debt.